Oligomeric Aβ-induced synaptic dysfunction in Alzheimer's disease

Topic: Disease mechanisms in lab and animal studies

Alzheimer's disease (AD) is a devastating disease characterized by synaptic and neuronal loss in the elderly. Compelling evidence suggests that soluble amyloid-β peptide (Aβ) oligomers induce synaptic loss in AD. Aβ-induced synaptic dysfunction is dependent on overstimulation of N-methyl-D-aspartate receptors (NMDARs) resulting in aberrant activation of redox-mediated events as well as elevation of cytoplasmic Ca2+, which in turn triggers downstream pathways involving phospho-tau (p-tau), caspases, Cdk5/dynamin-related protein 1 (Drp1), calcineurin/PP2B, PP2A, Gsk-3β, Fyn, cofilin, and CaMKII and causes endocytosis of AMPA receptors (AMPARs) as well as NMDARs. Dysfunction in these pathways leads to mitochondrial dysfunction, bioenergetic compromise and consequent synaptic dysfunction and loss, impaired long-term potentiation (LTP), and cognitive decline. Evidence also suggests that Aβ may, at least in part, mediate these events by causing an aberrant rise in extrasynaptic glutamate levels by inhibiting glutamate uptake or triggering glutamate release from glial cells. Consequent extrasynaptic NMDAR (eNMDAR) overstimulation then results in synaptic dysfunction via the aforementioned pathways. Consistent with this model of Aβ-induced synaptic loss, Aβ synaptic toxicity can be partially ameliorated by the NMDAR antagonists (such as memantine and NitroMemantine). PSD-95, an important scaffolding protein that regulates synaptic distribution and activity of both NMDA and AMPA receptors, is also functionally disrupted by Aβ. PSD-95 dysregulation is likely an important intermediate step in the pathological cascade of events caused by Aβ. In summary, Aβ-induced synaptic dysfunction is a complicated process involving multiple pathways, components and biological events, and their underlying mechanisms, albeit as yet incompletely understood, may offer hope for new therapeutic avenues.

Key findings

• Compelling evidence suggests that soluble amyloid-β peptide (Aβ) oligomers induce synaptic loss in AD.
• Evidence also suggests that Aβ may, at least in part, mediate these events by causing an aberrant rise in extrasynaptic glutamate levels by inhibiting glutamate uptake or triggering glutamate release from glial cells.
• Consequent extrasynaptic NMDAR (eNMDAR) overstimulation then results in synaptic dysfunction via the aforementioned pathways.

New to this subject? Start with our plain-English guide: Treatments →

Study details

• Evidence strengthLow

Read the original

• DOI: 10.1186/1750-1326-9-48
• PubMed: 25394486
• Original source →

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

@article{tu2014-25394486,
  author  = {Tu, S. and Okamoto, S. and Lipton, S. A. and Xu, H.},
  title   = {{Oligomeric Aβ-induced synaptic dysfunction in Alzheimer's disease}},
  journal = {Molecular neurodegeneration},
  year    = {2014},
  doi     = {10.1186/1750-1326-9-48},
  pmid    = {25394486},
  url     = {https://doi.org/10.1186/1750-1326-9-48}
}

Related studies in Treatments

• Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction Brain research · 1996-01-01 · usefulness score 36/100
• Phosphodiesterase Type 5 Inhibitors in Men With Erectile Dysfunction and the Risk of Alzheimer Disease: A Cohort Study Neurology · 2024-02-07 · usefulness score 76/100
• Stress-Specific Mitochondrial Reserve as a Candidate Modifier of Lipid-Driven Synaptic Failure in Alzheimer Disease Zenodo (CERN European Organization for Nuclear Research) · 2026-08-08 · usefulness score 66/100
• Clusterin secreted from astrocyte promotes excitatory synaptic transmission and ameliorates Alzheimer's disease neuropathology Molecular neurodegeneration · 2021-01-31 · usefulness score 43/100
• A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance The Lancet. Neurology · 2006-11-01 · usefulness score 40/100
• Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses The Journal of neuroscience : the official journal of the Society for Neuroscience · 2010-08-01 · usefulness score 36/100

Similar studies

• Role of Aβ in Alzheimer's-related synaptic dysfunction 2022 · Disease mechanisms
• Dysfunction of NMDA receptors in Alzheimer's disease 2016 · Disease mechanisms
• Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections 2012 · Treatments
• The role of the tripartite glutamatergic synapse in the pathophysiology of Alzheimer's disease 2015 · Digital health tools
• Memantine for the Treatment of Dementia: A Review on its Current and Future Applications 2018 · Treatments
• Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss 2013 · Risk factors

More on Treatments

• A review that covers this ground Redox modulation by S-nitrosylation contributes to protein misfolding, mitochondrial dynamics, and neuronal synaptic damage in neurodegenerative diseases Cell death and differentiation · 2011-05-20 · usefulness score 36/100
• Newest in this subject Opposing Regulation of Tau Condensation by Phosphorylation Levels and Molecular Chaperone Interactions bioRxiv · 2026-10-30 · Preprint — not yet peer-reviewed · usefulness score 16/100
• Newest in this subject Natural Sesquiterpenoids from Laggera pterodonta as bioactive Acetylcholinesterase Inhibitors: Insights from DFT, Molecular Docking, and ADMET Profiling Research Square · 2026-10-20 · Preprint — not yet peer-reviewed · usefulness score 16/100

See all studies in Treatments →